840 results on '"Napoli, N."'
Search Results
202. A further modification of the blumgart pancreatojejunostomy: results of a propensity score-matched analysis versus cattel-warren pancreatojejunostomy in open and robotic pancreatoduodenectomy.
- Author
-
Menonna, F., Napoli, N., Kauffmann, E.F., Cacace, C., Iacopi, S., Tudisco, A., Perrone, V.G., Vistoli, F., and Boggi, U.
- Subjects
- *
PANCREATICODUODENECTOMY , *ROBOTICS - Published
- 2021
- Full Text
- View/download PDF
203. Resection and reconstruction of the superior mesenteric artery resection during pancreatectomy: post-operative results and survival.
- Author
-
Cacace, C., Napoli, N., Kauffmann, E.F., Menonna, F., Iacopi, S., Tudisco, A., Perrone, V.G., Vistoli, F., and Boggi, U.
- Subjects
- *
MESENTERIC artery , *PANCREATECTOMY - Published
- 2021
- Full Text
- View/download PDF
204. Results of double-layer running suture hepatico-jejunostomy in pancreatoduodenectomy and total pancreatectomy.
- Author
-
Caputo, R., Napoli, N., Kauffmann, E.F., Cacace, C., Menonna, F., Tudisco, A., Perrone, V.G., Vistoli, F., and Boggi, U.
- Subjects
- *
PANCREATICODUODENECTOMY , *PANCREATECTOMY , *SUTURING , *SUTURES - Published
- 2021
- Full Text
- View/download PDF
205. A preoperative prognostic score based on a nomogram to predict survival in patients with locally advanced pancreatic ductal adenocarcinoma undergoing pancreatectomy with arterial resection.
- Author
-
Napoli, N., Kauffmann, E.F., Cacace, C., Menonna, F., Iacopi, S., Tudisco, A., Perrone, V.G., Vistoli, F., and Boggi, U.
- Subjects
- *
PANCREATECTOMY , *NOMOGRAPHY (Mathematics) , *ADENOCARCINOMA , *FORECASTING , *PATIENTS - Published
- 2021
- Full Text
- View/download PDF
206. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.
- Author
-
Chakhtoura, M., Napoli, N., and El Hajj Fuleihan, G.
- Subjects
COVID-19 pandemic ,VITAMIN D ,ZINC supplements ,CALCIUM supplements ,PANDEMICS ,RESPIRATORY infections ,COVID-19 ,VITAMIN D receptors - Published
- 2020
- Full Text
- View/download PDF
207. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
- Author
-
Armamento-Villareal R, Napoli N, Panwar V, and Novack D
- Published
- 2006
208. A propensity score-matched analysis of modified Blumgart vs Cattell-Warren duct-to-mucosa pancreatojejunostomy in robotic pancreatoduodenectomy.
- Author
-
Menonna, F., Napoli, N., Kauffmann, E., Iacopi, S., Lucchesi, M., Lombardo, C., Costa, F., and Boggi, U.
- Subjects
- *
ROBOTICS , *STATISTICAL power analysis - Abstract
B Background: b The modified Blumgart pancreatojejunostomy (mB-PJ) reduces the incidence of pancreatic fistula (POPF) in open pancreatoduodenectomy (PD), but no information is available for robotic PD. We present a propensity score-matched analysis of mB-PJ vs Cattell-Warren pancreatojejunostomy (CW-PJ) in robotic PD. CR-POPF occurred in no patient after mB-PJ and in 15 patients after CW-P (23.8%) (p=0.10, OR 0.12). [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
209. Prevalence of antibodies to hepatitis C virus among family members of patients with chronic hepatitis C
- Author
-
Napoli, N., Fiore, G., Vella, F., Fera, G., and Schiraldi, O.
- Abstract
In this study, 108 family members of 40 chronically HCV-infected patients (19 post-transfusion and 21 sporadic), and 45 families of 16 anti-HCV-negative index cases (control group) were tested for anti-HCV antibodies. Anti-HCV antibodies were found in 16 (14.8%) families of anti-HCV positive index cases (15% males and 14.6% females; p = NS), with no difference between families of index cases with post-transfusion and those with sporadic HCV infection. Out of the 16 anti-HCV positive family members, 12 (75%) had clinical and/or serological evidence of chronic liver damage. None of the control group subjects were anti-HCV-positive (p < 0.01). The rate of anti-HCV positivity was 34.4% among spouses, 14.3% among siblings, 16.7% among cohabitants and 2.3% among children; anti-HCV antibodies were not detected among parents. We found a positive correlation between the prevalence of anti-HCV antibodies among families and the severity of the HCV-related chronic liver damage of the index cases (p < 0.00005). In addition, to confirm that HCV infection and HCV-related chronic hepatitis may be transmitted intrafamiliarly, our findings also indicate that horizontal, especially sexual contact, is a more important route of HCV infection than vertical/perinatal transmission. Finally, the risk of acquiring HCV infection among families appears to be the highest when index cases are suffering from severe HCV-related chronic hepatitis.
- Published
- 1993
- Full Text
- View/download PDF
210. The problem of edema formation and resolution
- Author
-
Desanto, N. G., Giovambattista Capasso, Papalia, T., Napoli, N., Desanto, Ng, Capasso, Giovambattista, Papalia, T, and DE NAPOLI, N.
- Subjects
Edema ,Humans
211. A contribution to the history of common salt
- Author
-
Desanto, N. G., Bisaccia, C., Cirillo, M., Desanto, R. M., Desanto, L. S., Desanto, D., Teresa Papalia, Capasso, G., Napoli, N., Desanto, Ng, Bisaccia, C, Cirillo, Massimo, Desanto, Rm, Desanto, L, Desanto, D, Papalia, T, Capasso, G, DE NAPOLI, N., Cirillo, M, and Capasso, Giovambattista
- Subjects
Europe ,History, 17th Century ,Religion ,History, 16th Century ,Humans ,Sodium Chloride ,History, 18th Century ,Roman World ,History, Ancient - Abstract
Salt has influenced human nutrition, health, politics, taxation, economy, freight, transport, and commerce throughout the ages. All human activities have been influenced by salt including economy, religious beliefs and practices, art, literature, psychoanalysis, superstitions, and exorcism. Salt is recognized as a symbol for friendship, hospitality, chastity, alliance, table fellowship, fidelity, fertility, blessing, curse and endurance, etc. The Bible is the first book of salt and contains no fewer than 24 references to this substance. In the Gospels the parable of salt is a central one. Many many church fathers have written on salt a substance, which up to 1969 was a relevant element in the rite of Baptism. This paper reviews the importance of common salt for human life, and by drawing from various scientific and literary sources makes a special discussion of its various symbolisms.
212. Risultati preliminari sull'impiego della Tiapride nel trattamento della sindrome da astinenza da oppiacei
- Author
-
Bersani, Giuseppe, Albani, G., Graziano, G., Napoli, N., DI MAURO, M., Paolucci, P., Bersani, I., Grasso, G., Daniele, A., and Mergè, P. C.
- Published
- 1984
213. T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial
- Author
-
Cosman, F, Lewiecki, E. Michael, Ebeling, Peter R., Hesse, E, Napoli, N, Crittenden, Daria B., Rojeski, M, Yang, W, Libanati, C, and Ferrari, S
- Published
- 2020
- Full Text
- View/download PDF
214. Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIAB trial
- Author
-
Strollo R, Soare A, Manon Khazrai Y, Di Mauro A, Andrea Palermo, Del Toro R, Fallucca S, Giovanna Belluomo M, Dugo L, Pianesi M, Pozzilli P, and Napoli N
215. Computed tomography visceral adipose tissue volume measurements of Italians. Predictive equations
- Author
-
Armellini, F., Zamboni, M., Perdichizzi, G., antonio greco, Napoli, N., Pandolfo, I., Mondello, G., and Bosello, O.
- Subjects
Adult ,Male ,Adolescent ,Body Weight ,Middle Aged ,X-Ray Computed ,Body Mass Index ,Adipose Tissue ,Italy ,Body Constitution ,Humans ,Female ,Menopause ,Tomography, X-Ray Computed ,Tomography ,Aged - Abstract
To evaluate total visceral adipose tissue (AT) volumes in relation to single slices of visceral AT area measured at different levels and to other simple anthropometric measurements.Only outpatients examined in a metabolic unit were considered; subjects without conditions known to affect AT distribution who gave their informed consent were recruited.All subjects were hospitalized in the Department of Internal Medicine of the University of Messina.90 adult subjects of which 18 men and 42 pre- and 30 post-menopausal women. Ages ranged from 18 to 69 years and body mass indexes ranged from 22 to 50.The AT volume was calculated by computed tomography from the AT area of five scans and from the distances between these scans.AT area at the level of the 2nd-3rd lumbar vertebra had by itself the highest predictive power in men (s.e. = 6.8%), in post-menopausal women (s.e. = 7.4%) and, together with age, in pre-menopausal women (s.e. = 14%). Of the non-radiological parameters it was waist circumference, together with age, which showed the highest predictive power in men (s.e. = 21%), pre-menopausal women (s.e. = 25%) and, together with height, in post-menopausal women (s.e. = 33%).A single scan measurement at the lumbar level was confirmed to be representative of total visceral AT volume. Waist circumference was the non-radiological parameter that best correlated with volume.
216. Perspective on the clinical practice management of hypovitaminosis D from a meeting of Italian experts
- Author
-
Fassio, A., Bertoldo, F., Braga, V., Brandi, M. L., Calvieri, S., Cianferotti, L., Colao, A., D Amelio, P., D Avola, G. M., Esposti, L. D., Frediani, B., Giannini, S., Giusti, A., Gonnelli, S., Malavolta, N., Marcocci, C., Minisola, S., Napoli, N., Nuti, R., Passeri, G., Rossini, M., Sinigaglia, L., Viapiana, O., Francesco Vierucci, Gatti, D., Abdel Jaber, M., Benini, C., Boner, A., Bortolotti, R., Brigo, M., Catalano, A., Ferlin, A., Giollo, A., Girasole, G., Idolazzi, L., Lello, S., Maestri, E., Martinis, F., Muratore, M., Olivari, F., Peroni, D., Romagnoli, E., Ruggiero, C., Saviola, G., Sella, S., Sfrappini, M., Silveri, F., Vantaggiato, E., Venturin, A., and Zuccaro, C.
- Subjects
Fractures ,Osteoporosis ,Supplementation ,Vitamin D
217. Pathophysiology of Bone Fragility in Patients with Diabetes
- Author
-
Andrea Palermo, D'Onofrio L, Buzzetti R, Manfrini S, and Napoli N
218. An update on rickettsiosis
- Author
-
Manfredi RIZZO, Mansueto, P., Affronti, M., Sferrazza, C., Bucchieri, S., Napoli, N., Cusumano, G., Cannone, V., Catello, F., Rini, G. B., and Di Fede, G.
219. Sudden hearing loss and the risk of subsequent cerebral ischemic stroke
- Author
-
Andrea CIORBA, Aimoni, C., Crema, L., Maldotti, F., Napoli, N., Guerzoni, F., and Govoni, V.
- Subjects
sudden sensorineural hearing loss ,cerebral ischemic stroke ,SSNHL ,NO
220. Transfusion of stored red blood cells in critically ill trauma patients: A retrospective study
- Author
-
Savino Spadaro, Reverberi, R., Fogagnolo, A., riccardo ragazzi, Napoli, N., Marangoni, E., Bellini, Tiziana, and Carlo Volta
- Subjects
Adult ,Male ,Erythrocytes ,Multiple Trauma ,Critical Illness ,Blood transfusion ,Storage of red cells ,Length of Stay ,Middle Aged ,NO ,Intensive Care Units ,Erythrocyte Count ,Blood Banks ,Humans ,Female ,Hospital Mortality ,Erythrocyte Transfusion ,Storage of red cells, Blood transfusion, Trauma patients and outcome ,Trauma patients and outcome ,Aged ,Retrospective Studies - Abstract
The many published studies on the effects of the transfusion of stored red blood cells on clinical outcomes yielded discordant results. Therefore, we chose to study patients with severe trauma. The clinical outcomes considered included in-hospital mortality, the occurrence of sepsis, length of stay in intensive care unit and in hospital, and days of mechanical ventilation.We selected all patients with traumatic injury, who received at least 2 red cell units in the first day of admission. Patients were divided into two groups: those who had received fresh red cells only (fresh group) and those who had received at least one "old" red cell unit (old group). The red cells were considered fresh if they had been stored14 days.The fresh and old groups included 376 and 321 patients, respectively. Baseline demographic and clinical characteristics were comparable between the groups. However, old group received more red cell and plasma units during whole hospital stay (red cells: 11 ± 7 vs 6 ± 4, p0.001; plasma: 7 [0-9] vs 3 [0-6]). Among outcomes, only length of stay in intensive care unit (old vs fresh: 18 ± 9 vs 12 ± 8 days, p0.001) and in hospital (77 ± 35 vs 45 ± 30 days, p0.001) differed significantly between groups. The association remained statistically significant in a multivariate analysis including known confounding factors.Patients with major trauma transfused with old (≥14 days) red cells had a longer length of stay in intensive care unit and in hospital, without any difference in mortality, occurence of sepsis or days of mechanical ventilation.
221. EFFECTIVENESS OF CALCIUM CITRATE IN COMPARISON WITH CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM
- Author
-
Palermo, A., Tabacco, G., Vescini, F., Sanson, G., Giosuè Giordano Incognito, Falchetti, A., Bosco, D., Santonati, A., Pozzilli, P., Napoli, N., Manfrini, S., Trimboli, P., Mazziotti, G., Cesareo, R., and Naciu, A. M.
222. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
- Author
-
Rizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J., Napoli, N., Papapoulos, S., Reginster, J.-Y, Cooper, C., Rizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J., Napoli, N., Papapoulos, S., Reginster, J.-Y, and Cooper, C.
- Abstract
Summary: This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. Clinical case reports/reviews and case-control studies report this association, but retrospective phase III trial analyses show no increased risk. Bisphosphonate use may be associated with atypical subtrochanteric fractures, but the case is yet unproven. Introduction: A Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the International Osteoporosis Foundation has reviewed the evidence for a causal association between subtrochanteric fractures and long-term treatment with bisphosphonates, with the aim of identifying areas for further research and providing recommendations for physicians. Methods: A PubMed search of literature from 1994 to May 2010 was performed using key search terms, and articles pertinent to subtrochanteric fractures following bisphosphonate use were analysed. Results: Several clinical case reports and case reviews report a possible association between atypical fractures at the subtrochanteric region of the femur in bisphosphonate-treated patients. Common features of these ‘atypical' fractures include prodromal pain, occurrence with minimal/no trauma, a thickened diaphyseal cortex and transverse fracture pattern. Some small case-control studies report the same association, but a large register-based study and retrospective analyses of phase III trials of bisphosphonates do not show an increased risk of subtrochanteric fractures with bisphosphonate use. The number of atypical subtrochanteric fractures in association with bisphosphonates is an estimated one per 1,000 per year. It is recommended that physicians remain vigilant in assessing their patients treated with bisphosphonates for the treatment or prevention of osteoporosis and advise patients of the potential risks. Conclusions: Bisphosphonate use may be associated with atypical subtrochanteric fract
223. Cancer-associated bone disease
- Author
-
Rizzoli, R., Body, J.-J, Brandi, M.-L, Cannata-Andia, J., Chappard, D., El Maghraoui, A., Glüer, C., Kendler, D., Napoli, N., Papaioannou, A., Pierroz, D., Rahme, M., Van Poznak, C., de Villiers, T., El Hajj Fuleihan, G., Rizzoli, R., Body, J.-J, Brandi, M.-L, Cannata-Andia, J., Chappard, D., El Maghraoui, A., Glüer, C., Kendler, D., Napoli, N., Papaioannou, A., Pierroz, D., Rahme, M., Van Poznak, C., de Villiers, T., and El Hajj Fuleihan, G.
- Abstract
Bone is commonly affected in cancer. Cancer-induced bone disease results from the primary disease, or from therapies against the primary condition, causing bone fragility. Bone-modifying agents, such as bisphosphonates and denosumab, are efficacious in preventing and delaying cancer-related bone disease. With evidence-based care pathways, guidelines assist physicians in clinical decision-making. Of the 57 million deaths in 2008 worldwide, almost two thirds were due to non-communicable diseases, led by cardiovascular diseases and cancers. Bone is a commonly affected organ in cancer, and although the incidence of metastatic bone disease is not well defined, it is estimated that around half of patients who die from cancer in the USA each year have bone involvement. Furthermore, cancer-induced bone disease can result from the primary disease itself, either due to circulating bone resorbing substances or metastatic bone disease, such as commonly occurs with breast, lung and prostate cancer, or from therapies administered to treat the primary condition thus causing bone loss and fractures. Treatment-induced osteoporosis may occur in the setting of glucocorticoid therapy or oestrogen deprivation therapy, chemotherapy-induced ovarian failure and androgen deprivation therapy. Tumour skeletal-related events include pathologic fractures, spinal cord compression, surgery and radiotherapy to bone and may or may not include hypercalcaemia of malignancy while skeletal complication refers to pain and other symptoms. Some evidence demonstrates the efficacy of various interventions including bone-modifying agents, such as bisphosphonates and denosumab, in preventing or delaying cancer-related bone disease. The latter includes treatment of patients with metastatic skeletal lesions in general, adjuvant treatment of breast and prostate cancer in particular, and the prevention of cancer-associated bone disease. This has led to the development of guidelines by several societies and workin
224. Erratum to: Taxonomy of rare genetic metabolic bone disorders.
- Author
-
Masi, L., Agnusdei, D., Bilezikian, J., Chappard, D., Chapurlat, R., Cianferotti, L., Devolgelaer, J.-P., Maghraoui, A., Ferrari, S., Javaid, K., Kaufman, J.-M., Liberman, U., Lyritis, G., Miller, P., Napoli, N., Roldan, E., Papapoulos, S., Watts, N., and Brandi, M.
- Subjects
OSTEOPENIA ,DATA analysis - Abstract
A correction to the article "Taxonomy of Rare Genetic Metabolic Bone Disorders" that was published in the 2015 issue is presented.
- Published
- 2015
- Full Text
- View/download PDF
225. Vein Resection during Robotic Pancreatectomy for Borderline Resectable Pancreatic Cancer.
- Author
-
Ginesini, M., Kauffmann, E.F., Napoli, N., Gianfaldoni, C., Viti, V., Di Dato, A., Barbarello, L., Costa, F., Vistoli, F., and Boggi, U.
- Subjects
- *
PANCREATIC cancer , *PANCREATECTOMY , *VEINS , *ROBOTICS - Published
- 2023
- Full Text
- View/download PDF
226. Diagnosis and management of bone fragility in diabetes: an emerging challenge.
- Author
-
Ferrari, S.L., Abrahamsen, B., Napoli, N., Akesson, K., Chandran, M., Eastell, R., El-Hajj Fuleihan, G., Josse, R., Kendler, D.L., Kraenzlin, M., Suzuki, A., Pierroz, D.D., Schwartz, A.V., Leslie, W.D., and on behalf of the Bone and Diabetes Working Group of IOF
- Subjects
- *
DIABETES complications , *OSTEOPOROSIS diagnosis , *OSTEOPOROSIS treatment , *HYPOGLYCEMIC agents , *BONES , *OSTEOPOROSIS , *ALGORITHMS , *BIOMARKERS , *DIABETES , *SYMPTOMS , *BONE density , *TREATMENT effectiveness , *ADULTS , *DISEASE risk factors , *ANATOMY - Abstract
Fragility fractures are increasingly recognized as a complication of both type 1 and type 2 diabetes, with fracture risk that increases with disease duration and poor glycemic control. Yet the identification and management of fracture risk in these patients remains challenging. This review explores the clinical characteristics of bone fragility in adults with diabetes and highlights recent studies that have evaluated bone mineral density (BMD), bone microstructure and material properties, biochemical markers, and fracture prediction algorithms (i.e., FRAX) in these patients. It further reviews the impact of diabetes drugs on bone as well as the efficacy of osteoporosis treatments in this population. We finally propose an algorithm for the identification and management of diabetic patients at increased fracture risk. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
227. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial.
- Author
-
Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P, IMDIAB Group, Bizzarri, Carla, Pitocco, Dario, Napoli, Nicola, Di Stasio, Enrico, Maggi, Daria, Manfrini, Silvia, Suraci, Concetta, and Cavallo, Maria Gisella
- Abstract
Objective: We investigated whether supplementation of the active form of vitamin D (calcitriol) in recent-onset type 1 diabetes can protect beta-cell function evaluated by C-peptide and improve glycemic control assessed by A1C and insulin requirement.Research Design and Methods: Thirty-four subjects (aged 11-35 years, median 18 years) with recent-onset type 1 diabetes and high basal C-peptide >0.25 nmol/l were randomized in a double-blind trial to 0.25 microg/day calcitriol or placebo and followed-up for 2 years.Results: At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group. C-peptide dropped significantly (P < 0.001) but similarly in both groups, with no significant differences at each time point.Conclusions: At the doses used, calcitriol is ineffective in protecting beta-cell function in subjects (including children) with recent-onset type 1 diabetes and high C-peptide at diagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
228. A.149 - Study of dosimetric improvement in lung SBRT using a 6-degree of freedom couch in IGRT.
- Author
-
Menna, S., Alitto, A.R., Chiesa, S., Teodoli, S., Mattiucci, G.C., Di Napoli, N., De Filippo, L., Balducci, M., Valentini, V., Piermattei, A., and Azario, L.
- Published
- 2016
- Full Text
- View/download PDF
229. Erratum to: Serum chitotriosidase in postmenopausal women with severe osteoporosis.
- Author
-
Musumeci, M., Palermo, A., D'Onofrio, L., Greto, V., Maddaloni, E., Napoli, N., Manfrini, S., Vadalà, G., Denaro, V., Stasio, E., Rosa, M., Tibullo, D., and Angeletti, S.
- Subjects
GLYCOSIDASES ,OSTEOPOROSIS ,WOMEN ,POSTMENOPAUSE - Abstract
An correction to the article "Serum chitotriosidase in postmenopausal women with severe osteoporosis" that was published online in the January 19, 2016 issue is presented.
- Published
- 2016
- Full Text
- View/download PDF
230. Calo ponderale, esercizio o entrambi ed efficienza fisica in soggetti anziani obesi
- Author
-
Villareal, D., Chode, S., Parimi, N., Sinacore, D., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., Shah, K., and Fierabracci, Paola
- Published
- 2011
- Full Text
- View/download PDF
231. O51 Prevalence of vitamin D deficiency in Sicilian postmenopausal women
- Author
-
Carmina, E., Napoli, N., Cusumano, G., Vitale, G., Avila, D., Sutera, L., Rini, G.B., and Di Fede, G.
- Published
- 2004
232. Deciphering the value of trans-anastomotic stents for advanced-risk pancreatoduodenectomy.
- Author
-
Cannas, S., Perri, G., El Asmar, R., Di Dato, A., Napoli, N., Paniccia, A., Salvia, R., Marchegiani, G., Zureikat, A.H., Boggi, U., and Vollmer, C.M.
- Published
- 2024
- Full Text
- View/download PDF
233. Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults.
- Author
-
Armamento-Villareal, R., Aguirre, L., Napoli, N., Shah, K., Hilton, T., Sinacore, D., Qualls, C., and Villareal, D.
- Subjects
- *
ACADEMIC medical centers , *ANALYSIS of variance , *STATISTICAL correlation , *DIET , *FISHER exact test , *FRAIL elderly , *MULTIVARIATE analysis , *MUSCLES , *NUTRITION , *OBESITY , *REGRESSION analysis , *RESEARCH funding , *THIGH , *BONE density , *LIFESTYLES , *DATA analysis software , *DESCRIPTIVE statistics - Abstract
Summary: We studied the relationships among strength, muscle mass, and bone mineral density (BMD) with lifestyle change. Lifestyle therapy consisted of exercise, diet, and diet plus exercise. Diet was by caloric restriction to induce and maintain a weight loss of 10 % from baseline body weight. Exercise attenuated weight loss-induced muscle and bone losses. Exercise improved strength despite muscle loss in patients on diet and exercise. Changes in strength did not correlate with changes in BMD. However, changes in thigh muscle volume correlated with, and predicted changes in hip BMD. Introduction: Losses of hip BMD and lean body mass are major complications of lifestyle therapy in frail, obese older adults; however, the contribution of mechanical strain loss from muscle loss is poorly defined. We determined the effect of changes in thigh muscle volume and muscle strength on BMD in frail, obese older adults undergoing lifestyle therapy aimed at intentional weight loss with or without exercise. Methods: One hundred seven obese older adults were randomized to control, diet, exercise, and diet-exercise groups for 1 year. Thigh muscle volume was measured by magnetic resonance imaging, BMD by DXA, knee strength by dynamometry, total strength by one-repetition maximum (1-RM), and bone markers by immunoassay. Results: Thigh muscle volume decreased in the diet group (−6.2 ± 4.8 %) and increased in the exercise group (2.7 ± 3.1 %), while it was not significantly different from the control in the diet-exercise group. Changes in hip BMD followed similar pattern as those in thigh muscle volume. Knee extension and flexion increased in the exercise group (23 ± 20 %; 25 ± 19 %) and diet-exercise group (20 ± 19 %; 20.6 ± 27 %) but were unchanged in the control and diet groups. Changes in thigh muscle volume correlated with changes in hip BMD ( r = 0.55, P = <0.001) and were an independent predictor of changes in hip BMD ( β = 0.12, P = 0.03) in the multiple regression analyses after accounting for demographic factors and changes in weight and physical activity. There were no correlations between BMD changes and knee strength, 1-RM, and sclerostin changes. Conclusions: Changes in thigh muscle volume predict hip BMD changes in obese older patients undergoing lifestyle therapy. The effect of exercise in attenuating thigh muscle loss when added to diet may in part account for the reduction in weight loss-induced bone loss in the diet-exercise group. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
234. Echo doppler assessment of cardiac performance and carotid atherosclerosis in hypertensives on maintenance hemodialysis
- Author
-
Grandinetti, O., Cassani, S., Cosentino, G., Papalia, T., De Napoli, N., and Feraco, E.
- Published
- 1995
- Full Text
- View/download PDF
235. Bone turnover markers: understanding their value in clinical trials and clinical practice.
- Author
-
Civitelli, R., Armamento-Villareal, R., and Napoli, N.
- Subjects
- *
CLINICAL trials , *BONE diseases , *MEDICAL research , *OSTEOPOROSIS , *BONE fractures , *BONE resorption - Abstract
While bone mineral density (BMD) by dual-energy X-ray absorptiometry is the primary method of determining fracture risk, assessing bone turnover may add valuable information for the management of patients with low bone mass. Bone turnover markers (BTMs) are used in clinical trials where they can provide essential information on the biological efficacy of osteoporosis treatments. In such population-based studies, BTMs can predict fracture risk independent of BMD. When combined with BMD, they improve the fracture risk estimate above and beyond BMD alone in postmenopausal osteoporotic women. Since changes in bone turnover after the initiation of therapy with bone resorption inhibitors occur much more rapidly than changes in BMD, treatment efficacy could, in theory, be determined within weeks of using BTMs. However, such predictive value is limited by the large biological variability of these biochemical markers, even though newer automated methods have reduced their analytical variability. Consequently, widespread adoption as a means of predicting treatment efficacy in fracture prevention for individual patients cannot yet be recommended. BTMs may be useful for monitoring adherence to antiresorptive therapy and may aid in identifying patients for whom antiresorptive therapy is most appropriate. Thus, although BTMs are currently confined to clinical research applications, further improvement in assay precision may extend their diagnostic value in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
236. Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major.
- Author
-
Carmina, E., Di Fede, G., Napoli, N., Renda, G., Vitale, G., Lo Pinto, C., Bruno, D., Malizia, R., and Rini, G. B.
- Subjects
- *
HYPOGONADISM , *HORMONE therapy , *THALASSEMIA , *BONES , *GONADOTROPIN , *SEX hormones - Abstract
We studied bone mass and metabolism in 30 adult women (age 28.5 ± 1.3) with thalassemia major (TM) and evaluated whether prolonged hormone replacement therapy (HRT) was able to optimize bone accrual. TM patients had reduced bone mass, increased bone turnover and lower serum gonadotropin and estradiol levels compared with 10 normal women of similar age. A significant correlation was found between bone mass and sex hormone levels. Six TM patients with normal ovarian function had normal bone turnover markers and modestly low bone mass (lumbar spine -1.29 ± 0.31; femoral neck -0.60±0.21; Z-score). The other 24 TM women were hypogonadic and had significantly lower bone mass for age (lumbar spine -2.35 ± 0.2, femoral neck -1.83 ± 0.2) and increased bone turnover relative to eugonadal women. Of the hypogonadal patients, 13 had taken HRT since age 15 ± 1 years, but their bone mass and turnover markers were not different than untreated hypogonadal patients. In conclusion, while hypogonadism negatively affects bone mass acquisition in adult TM women, HRT at the standard replacement doses is not sufficient to secure optimal bone accrual. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
237. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study
- Author
-
Michele Barone, Antonio Massimo Ippolito, Angelo Andriulli, Ruggiero Francavilla, Francesco Pesce, Paolo Tundo, Antonio Patrizio Termite, Nicola Napoli, Pietro Gatti, Gianfranco Lauletta, Michele Milella, Endrit Shahini, A. Smedile, Vincenzo Messina, Filomena Morisco, Fabio Conti, Giuseppina Brancaccio, A. Di Leo, Teresa Santantonio, C. Masetti, Andrea Iannone, Barone, M., Iannone, A., Shahini, E., Ippolito, A. M., Brancaccio, G., Morisco, F., Milella, M., Messina, V., Smedile, A., Conti, F., Gatti, P., Santantonio, T., Tundo, Antonio, Lauletta, G., Napoli, N., Masetti, C., Termite, A. P., Francavilla, R., Di Leo, A., Pesce, F., Andriulli, A., Barone, M, Iannone, A, Shahini, E, Ippolito, A M, Brancaccio, G, Morisco, F, Milella, M, Messina, V, Smedile, A, Conti, F, Gatti, P, Santantonio, T, Tundo, P, Lauletta, G, Napoli, N, Masetti, C, Termite, A P, Francavilla, R, Di Leo, A, Pesce, F, and Andriulli, A
- Subjects
Liver Cirrhosis ,Male ,Cirrhosis ,Sofosbuvir ,Sustained Virologic Response ,Gastroenterology ,Benzimidazole ,chemistry.chemical_compound ,0302 clinical medicine ,Ascites ,antiviral therapy ,Clinical endpoint ,Prospective Studies ,Chronic ,Prospective cohort study ,Hepatitis C ,Middle Aged ,Infectious Diseases ,Treatment Outcome ,030220 oncology & carcinogenesis ,Combination ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,Female ,medicine.symptom ,medicine.drug ,Human ,Ledipasvir ,medicine.medical_specialty ,Genotype ,Infectious Disease ,Antiviral Agents ,03 medical and health sciences ,direct-acting antivirals ,hepatitis C ,liver cirrhosis ,Aged ,Benzimidazoles ,Fluorenes ,Hepatitis C, Chronic ,Humans ,Ribavirin ,Drug Therapy ,Internal medicine ,Virology ,medicine ,Antiviral Agent ,direct-acting antiviral ,Hepatology ,business.industry ,liver cirrhosi ,medicine.disease ,Surgery ,Fluorene ,Prospective Studie ,chemistry ,business - Abstract
The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype 1b-infected patients with cirrhosis is still under debate. Our primary endpoint was to compare the sustained virological response at post-treatment week 12 (SVR12) of sofosbuvir-ledipasvir in combination with ribavirin for 12 weeks, and sofosbuvir-ledipasvir alone for 24 weeks. This was a prospective observational study that enrolled 424 (195 naive, 229 experienced; 164 treated for 12 weeks with Ribavirin and 260 with sofosbuvir-ledipasvir alone for 24 weeks) consecutive HCV genotype 1b-infected patients with cirrhosis. The SVR12 rates were 93.9% and 99.2% in patients treated for 12 and 24 weeks, respectively (p=0.002). The baseline characteristics of patients treated for 12 weeks were significantly different from those treated for 24 weeks as regards their younger age (p=0.002), prevalence of Child-Pugh class A (p=0.002), lower MELD scores (p=0.001) and smaller number of non-responders (p=0.04). The shorter treatment was significantly associated with a lower SVR12 in univariate and multivariate analysis (p=0.007 and p=0.008, respectively). The SVR rate was unaffected by age, gender, BMI, Child-Pugh class, MELD score or previous antiviral treatment. Patients receiving ribavirin experienced more episodes of ascites and headache but less recurrence of hepatocellular carcinoma (HCC), and were prescribed more diuretics and cardiopulmonary drugs. No patient discontinued treatment. The therapeutic regimen of sofosbuvir-ledipasvir plus ribavirin administered for 12 weeks was less effective than sofosbuvir-ledipasvir alone given for 24 weeks. At odds with European guidelines, the recommended 12-week treatment with sofosbuvir-ledipasvir alone might be suboptimal for this setting of patients. This article is protected by copyright. All rights reserved.
- Published
- 2018
238. Gemcitabine‐based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score‐matched cohort study.
- Author
-
Moekotte, A. L., Malleo, G., Roessel, S., Bonds, M., Halimi, A., Zarantonello, L., Napoli, N., Dreyer, S. B., Wellner, U. F., Bolm, L., Mavroeidis, V. K., Robinson, S., Khalil, K., Ferraro, D., Mortimer, M. C., Harris, S., Al‐Sarireh, B., Fusai, G. K., Roberts, K. J., and Fontana, M.
- Subjects
- *
ADJUVANT chemotherapy , *COHORT analysis , *ADENOCARCINOMA , *REGRESSION analysis - Abstract
Background: Whether patients who undergo resection of ampullary adenocarcinoma have a survival benefit from adjuvant chemotherapy is currently unknown. The aim of this study was to compare survival between patients with and without adjuvant chemotherapy after resection of ampullary adenocarcinoma in a propensity score‐matched analysis. Methods: An international multicentre cohort study was conducted, including patients who underwent pancreatoduodenectomy for ampullary adenocarcinoma between 2006 and 2017, in 13 centres in six countries. Propensity scores were used to match patients who received adjuvant chemotherapy with those who did not, in the entire cohort and in two subgroups (pancreatobiliary/mixed and intestinal subtypes). Survival was assessed using the Kaplan–Meier method and Cox regression analyses. Results: Overall, 1163 patients underwent pancreatoduodenectomy for ampullary adenocarcinoma. After excluding 187 patients, median survival in the remaining 976 patients was 67 (95 per cent c.i. 56 to 78) months. A total of 520 patients (53·3 per cent) received adjuvant chemotherapy. In a propensity score‐matched cohort (194 patients in each group), survival was better among patients who received adjuvant chemotherapy than in those who did not (median survival not reached versus 60 months respectively; P = 0·051). A survival benefit was seen in patients with the pancreatobiliary/mixed subtype; median survival was not reached in patients receiving adjuvant chemotherapy and 32 months in the group without chemotherapy (P = 0·020). Patients with the intestinal subtype did not show any survival benefit from adjuvant chemotherapy. Conclusion: Patients with resected ampullary adenocarcinoma may benefit from gemcitabine‐based adjuvant chemotherapy, but this effect may be reserved for those with the pancreatobiliary and/or mixed subtype. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
239. Improved percent-predicted peak VO2 is associated with lower risk of hospitalization in patients with coronary heart disease. Analysis from the FRIEND registry.
- Author
-
Chiaranda, G., Myers, J., Arena, R., Kaminsky, L., Sassone, B., Pasanisi, G., Mandini, S., Pizzolato, M., Franchi, M., Napoli, N., Guerzoni, F., Caruso, L., Mazzoni, G., and Grazzi, G.
- Subjects
- *
CARDIAC patients , *PATIENT readmissions , *OXYGEN consumption , *HOSPITAL care , *CORONARY disease - Abstract
Normal standards for peak oxygen consumption (VO 2 peak) are controversial because they tend to be population and protocol specific. This study was undertaken to examine the association between percentage of age-predicted VO 2 peak and all-cause hospital readmission in cardiac outpatients who were referred to an exercise-based secondary prevention program. Hospital readmission was assessed in 1283 male patients with coronary heart disease (CHD) three years after enrolment, and related to the age-predicted VO 2 peak derived from the Fitness Registry and the Importance of Exercise: A National Data Base equation (FRIEND %PRED). VO 2 peak was estimated using a moderate perceptually regulated 1-km treadmill-walking test. Readmission was also assessed during the fourth-to-sixth years as function of improvement in FRIEND %PRED in 845 patients who were re-evaluated 3 years after baseline. During the 3-years after baseline, readmission rate was lower across increasing tertiles of FRIEND %PRED. Compared to the lowest tertile, the adjusted hazard ratios (HRs) for the second and third tertile were 0.98 (95% CI 0.76–1.27, p = 0.90) and 0.71 (0.53–0.95, p = 0.002). The rate of readmission from the fourth-to-sixth years after baseline was lower across tertiles of improved FRIEND %PRED , with adjusted HRs 0.78 (0.60–1.03, p = 0.08) and 0.58 (0.42–0.75, p < 0.0001) for the intermediate and high tertiles vs the lowest tertile. After adjustment for confounders, every 1 unit % increase in FRIEND %PRED was associated with a 3% reduction in risk of readmission (HR 0.97, 0.95–0.98, p < 0.0001). Age-predicted VO 2 peak estimated by a moderate treadmill-walk predicts hospital readmission in outpatients with CHD undergoing secondary prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
240. Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors.
- Author
-
Marcucci, G, Beltrami, G, Tamburini, A, Body, J J, Confavreux, C B, Hadji, P, Holzer, G, Kendler, D, Napoli, N, Pierroz, D D, Rizzoli, R, and Brandi, M L
- Subjects
- *
CHILDHOOD cancer , *TRANCE protein , *CANCER patients - Published
- 2019
- Full Text
- View/download PDF
241. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
- Author
-
Barone, M., Iannone, A., Shahini, E., Ippolito, A. M., Brancaccio, G., Morisco, F., Milella, M., Messina, V., Smedile, A., Conti, F., Gatti, P., Santantonio, T., Tundo, P., Lauletta, G., Napoli, N., Masetti, C., Termite, A. P., Francavilla, R., Di Leo, A., and Pesce, F.
- Subjects
- *
HEPATITIS C treatment , *HEPATITIS C , *TREATMENT of cirrhosis of the liver , *COMBINATION drug therapy , *GENOTYPES , *GENETICS ,SOFOSBUVIR - Abstract
The effectiveness of a 12-week course of sofosbuvir-ledipasvir in treatment-experienced HCV genotype 1b-infected patients with cirrhosis is still under debate. Our primary endpoint was to compare the sustained virological response at post-treatment week 12 ( SVR12) of sofosbuvir-ledipasvir in combination with ribavirin for 12 weeks, and sofosbuvir-ledipasvir alone for 24 weeks. This was a prospective observational study that enrolled 424 (195 naive, 229 experienced; 164 treated for 12 weeks with Ribavirin and 260 with sofosbuvir-ledipasvir alone for 24 weeks) consecutive HCV genotype 1b-infected patients with cirrhosis. The SVR12 rates were 93.9% and 99.2% in patients treated for 12 and 24 weeks, respectively ( P = .002). The baseline characteristics of patients treated for 12 weeks were significantly different from those treated for 24 weeks as regards their younger age ( P = .002), prevalence of Child-Pugh class A ( P = .002), lower MELD scores ( P = .001) and smaller number of nonresponders ( P = .04). The shorter treatment was significantly associated with a lower SVR12 in univariate and multivariate analyses ( P = .007 and P = .008, respectively). The SVR rate was unaffected by age, gender, BMI, Child-Pugh class, MELD score or previous antiviral treatment. Patients receiving ribavirin experienced more episodes of ascites and headache but less recurrence of hepatocellular carcinoma ( HCC), and were prescribed more diuretics and cardiopulmonary drugs. No patient discontinued treatment. The therapeutic regimen of sofosbuvir-ledipasvir plus ribavirin administered for 12 weeks was less effective than sofosbuvir-ledipasvir alone given for 24 weeks. At odds with European guidelines, the recommended 12-week treatment with sofosbuvir-ledipasvir alone might be suboptimal for this setting of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
242. Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel
- Author
-
Fabio Massimo Ulivieri, Nicola Napoli, Giuseppe Banfi, Anna Maria Formenti, Annamaria Colao, Stefano Frara, Andrea Giustina, Giovanni Lombardi, Valentina Camozzi, Ulivieri, F. M., Banfi, G., Camozzi, V., Colao, A., Formenti, A. M., Frara, S., Lombardi, G., Napoli, N., and Giustina, A.
- Subjects
2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Endocrinology, Diabetes and Metabolism ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030209 endocrinology & metabolism ,Disease ,Bone health ,G.I.O.S.E.G ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Pandemic ,VITD ,Vitamin D and neurology ,Medicine ,Humans ,Scientific debate ,Vitamin D ,Pandemics ,Sars-Cov-2 ,business.industry ,Position statement/Guideline ,COVID-19 ,Vitamins ,030220 oncology & carcinogenesis ,Family medicine ,business - Abstract
Vitamin D (VITD) is a key hormone for bone health and has relevant extra-skeletal effects that might play a role in the prevention and treatment of COronaVIrus Disease 19 (COVID-19). Literature regarding this scenario is voluminous but controversial. Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group (G.I.O.S.E.G) has been present in the scientific debate about the use of VITD and has regularly interfaced national regulatory agencies to ensure appropriateness of its employment. Given the current pandemic and the questions on COVID-19 and VITD, G.I.O.S.E.G. appointed an expert panel to advise how to consider this issue best. The results of these deliberations are reported in the current recommendation paper.
- Published
- 2021
243. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19
- Author
-
Varta Babalyan, Nandini Nair, Daniel D. Bikle, Martin Hewison, Accili Domenico, Marise Lazaretti-Castro, Nicola Napoli, Nicholas Hutchings, Donald W. Landry, Neil Binkley, Anna Maria Formenti, Mahesh V. Madhavan, Aakriti Gupta, Andrea Giustina, John P. Bilezikian, Bilezikian, J. P., Bikle, D., Hewison, M., Lazaretti-Castro, M., Formenti, A. M., Gupta, A., Madhavan, M. V., Nair, N., Babalyan, V., Hutchings, N., Napoli, N., Accili, D., Binkley, N., Landry, D. W., and Giustina, A.
- Subjects
Vitamin ,medicine.medical_specialty ,T-Lymphocytes ,Endocrinology, Diabetes and Metabolism ,Pneumonia, Viral ,030209 endocrinology & metabolism ,Disease ,Adaptive Immunity ,T-Lymphocytes, Regulatory ,Defensins ,Betacoronavirus ,03 medical and health sciences ,chemistry.chemical_compound ,Th2 Cells ,0302 clinical medicine ,Endocrinology ,Cathelicidins ,Immunity ,Internal medicine ,Autophagy ,medicine ,Vitamin D and neurology ,Humans ,Vitamin D ,Lung ,Pandemics ,SARS-CoV-2 ,business.industry ,COVID-19 ,General Medicine ,Th1 Cells ,medicine.disease ,Acquired immune system ,Immunity, Innate ,Cytokine release syndrome ,chemistry ,030220 oncology & carcinogenesis ,Th17 Cells ,Immunocompetence ,Coronavirus Infections ,Cytokine Release Syndrome ,business ,Cytokine storm ,Antimicrobial Cationic Peptides - Abstract
The SARS-CoV-2 virus responsible for the COVID-19 pandemic has generated an explosion of interest both in the mechanisms of infection leading to dissemination and expression of this disease, and in potential risk factors that may have a mechanistic basis for disease propagation or control. Vitamin D has emerged as a factor that may be involved in these two areas. The focus of this article is to apply our current understanding of vitamin D as a facilitator of immunocompetence both with regard to innate and adaptive immunity and to consider how this may relate to COVID-19 disease. There are also intriguing potential links to vitamin D as a factor in the cytokine storm that portends some of the most serious consequences of SARS-CoV-2 infection, such as the acute respiratory distress syndrome. Moreover, cardiac and coagulopathic features of COVID-19 disease deserve attention as they may also be related to vitamin D. Finally, we review the current clinical data associating vitamin D with SARS-CoV-2 infection, a putative clinical link that at this time must still be considered hypothetical.
- Published
- 2020
244. Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition.
- Author
-
Epstein, S., Defeudis, G., Manfrini, S., Napoli, N., and Pozzilli, P.
- Subjects
- *
BONE fracture prevention , *DIABETES complications , *DISEASE risk factors , *BIOLOGICAL models , *BONE growth , *CHARCOT joints , *CONFERENCES & conventions , *CYTOKINES , *BONE fractures , *GASTROINTESTINAL hormones , *SEX hormones , *INSULIN , *KIDNEY transplantation , *NEUROPEPTIDES , *OBESITY , *OSTEOPOROSIS , *PANCREAS transplantation , *RISK assessment , *SEROTONIN , *VITAMIN D , *GLUCAGON-like peptide 1 , *LEPTIN , *OXIDATIVE stress , *GHRELIN , *BONE density , *ADIPONECTIN , *RESISTIN , *SIGNAL peptides , *PHOTON absorptiometry - Abstract
Summary: Diabetes and osteoporosis are rapidly growing diseases. The link between the high fracture incidence in diabetes as compared with the non-diabetic state has recently been recognized. While this review cannot cover every aspect of diabetic osteodystrophy, it attempts to incorporate current information from the First International Symposium on Diabetes and Bone presentations in Rome in 2014. Diabetes and osteoporosis are fast-growing diseases in the western world and are becoming a major problem in the emerging economic nations. Aging of populations worldwide will be responsible for an increased risk in the incidence of osteoporosis and diabetes. Furthermore, the economic burden due to complications of these diseases is enormous and will continue to increase unless public awareness of these diseases, the curbing of obesity, and cost-effective measures are instituted. The link between diabetes and fractures being more common in diabetics than non-diabetics has been widely recognized. At the same time, many questions remain regarding the underlying mechanisms for greater bone fragility in diabetic patients and the best approach to risk assessment and treatment to prevent fractures. Although it cannot cover every aspect of diabetic osteodystrophy, this review will attempt to incorporate current information particularly from the First International Symposium on Diabetes and Bone presentations in Rome in November 2014. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
245. Serum chitotriosidase in postmenopausal women with severe osteoporosis.
- Author
-
Musumeci, M., Palermo, A., D'Onofrio, L., Greto, V., Maddaloni, E., Napoli, N., Manfrini, S., Vadalà, G., Denaro, V., Di Stasio, E., Di Rosa, M., Tibullo, D., and Silvia, A.
- Subjects
- *
SPINE radiography , *BIOMARKERS , *FEMUR , *FEMUR neck , *BONE fractures , *GLYCOSIDASES , *MULTIVARIATE analysis , *OSTEOPENIA , *OSTEOPOROSIS , *PARATHYROID hormone , *PEPTIDES , *STATISTICS , *X-rays , *DATA analysis , *BONE density , *CROSS-sectional method , *SEVERITY of illness index , *POSTMENOPAUSE , *PHOTON absorptiometry , *DISEASE complications - Abstract
Summary: Human chitotriosidase (Chit) increases during the osteoclast differentiation and their activity. We demonstrated that serum Chit was significantly higher in osteoporotic subjects than in healthy control ones and revealed a negative correlation between Chit and bone mineral density (BMD). This is the first study showing a correlation between Chit and severe postmenopausal osteoporosis. Introduction: Mammalian chitinases exert important biological roles in the monocyte lineage and chronic inflammatory diseases. In particular, Chit seems to promote bone resorption in vitro. No in vivo studies have been performed to confirm this finding. We aim to evaluate Chit activity in postmenopausal women affected by severe osteoporosis. Methods: In this cross-sectional study, 91 postmenopausal women affected by osteoporosis and 61 with either osteopenia or normal BMD were screened. All subjects were assessed by dual-energy X-ray absorptiometry (DXA) and X-ray vertebral morphometry. Osteoporotic subjects were considered eligible if they were affected by at least one vertebral osteoporotic fracture (group A = 57 subjects). Osteopenic or healthy subjects were free from osteoporotic fractures (group B = 51 subjects). Enzymatic Chit and serum β-CrossLaps (CTX) were measured in the whole population. Results: Group A showed higher serum levels of beta-CTX compared to group B (0.40 ± 0.26 ng/mL vs 0.29 ± 0.2 ng/mL, p = 0.022). Chit was significantly higher in group A than in group B (1042 ± 613 nmol/mL/h vs 472 ± 313 nmol/mL/h, p < 0.001, respectively) even after adjustment for age ( p < 0.001). Spearman correlation test revealed a negative correlation between Chit and BMD at each site (lumbar spine: r = −0.38, p = 0.001, femoral neck: r = −0.35, p = 0.001, total femur: r = −0.39, p < 0.001). Furthermore, a positive correlation between Chit and PTH was observed (r = 0.26, p = 0.013). No significant correlation was found between Chit and beta-CTX (r = 0.12, p = 0.229). After a multivariate analysis, a positive correlation between severe osteoporosis and Chit ( p < 0.001), beta-CTX ( p = 0.013), and age ( p < 0.001) was observed. Conclusion: This is the first clinical study showing a correlation between Chit and severe postmenopausal osteoporosis. Larger and prospective studies are needed to evaluate if Chit may be a promising clinical biomarker and/or therapeutic monitor in subjects with osteoporosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
246. Short- and Long-term Outcomes after Robotic and Laparoscopic Liver Resection for Malignancies: A Propensity Score-Matched Study
- Author
-
Eylon Lahat, Ugo Boggi, Antonella Tudisco, Chetana Lim, Claudio Ricci, Chady Salloum, Daniel Azoulay, Michael Osseis, Niccolò Napoli, Lim C., Salloum C., Tudisco A., Ricci C., Osseis M., Napoli N., Lahat E., Boggi U., and Azoulay D.
- Subjects
Male ,Laparoscopic surgery ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Blood transfusion ,Matched-Pair Analysis ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Robotic Surgical Procedures ,medicine ,Hepatectomy ,Humans ,Blood Transfusion ,Propensity Score ,Survival rate ,Aged ,Female ,Length of Stay ,Liver Neoplasms ,Margins of Excision ,Middle Aged ,Laparoscopy ,business.industry ,Carcinoma ,Hepatocellular ,robotic surgery, laparoscopic surgery ,Surgery ,Cardiac surgery ,Cardiothoracic surgery ,030220 oncology & carcinogenesis ,Propensity score matching ,Resection margin ,030211 gastroenterology & hepatology ,business ,Abdominal surgery - Abstract
Objectives: A laparoscopic approach improves short-term outcomes and maintains long-term outcomes compared to an open approach. In turn, the recent development of robotic surgery raises the question whether it performs as well as laparoscopic surgery. The aim of this study was to compare the short- and long-term outcomes of laparoscopic liver resection (LLR) and robotic liver resection (RLR) for malignancies. Method: From 2011 to 2017, the study population included 111 patients in the LLR group and 61 in the RLR group. Short- and long-term outcomes were compared before and after propensity score matching (PSM). Results: Operative mortality rate was nil. The intraoperative blood transfusion rate was higher during RLR (15% vs. 2%, p = 0.0009). Major morbidity and hospital stay were not different between the two groups. The resection margin width (LLR 7mm vs. RLR 10mm, p = 0.13) and R1 resection rates (resection margin width < 1mm; LLR 15% vs. RLR 11%, p = 0.49) were similar. After PSM (55 patients in each group), the blood transfusion, major morbidity, hospital stay and R1 resection were similar between the two groups. When considering the largest subset of patients with hepatocellular carcinoma including 114 patients (66%), the 3-year overall survival rate was 80% in the LLR group and 97% in the RLR group (p = 0.10) and remained similar after PSM (p = 0.27). The 3-year recurrence-free survival rate was 50% in the LLR group and 64% in the RLR group (p = 0.30) and remained similar after PSM (p = 0.26). Conclusions: No differences were found in blood transfusion, incidence of positive resection margins and long-term outcomes between the two techniques. RLR does not compromise short-term and oncologic outcomes in patients with liver cancers.
- Published
- 2019
247. Impact of Lymph Node Ratio on Survival in the Histopathological Subtypes of Resected Ampullary Cancer: A Retrospective International Multicenter Cohort Study.
- Author
-
Lemmers, D.H., Malleo, G., Khalil, K., Robinson, S., Nappo, G., Gradinariu, G., Bonds, M., Halimi, A., Mortimer, M., Mavroeidis, V.K., Napoli, N., Burdio, F., Bolm, L., Wellner, U., Pessaux, P., Ielpo, B., Boggi, U., Soonawalla, Z., Al-Sarireh, B., and Jamieson, N.B.
- Subjects
- *
HISTOPATHOLOGY , *LYMPH nodes , *COHORT analysis ,BILIARY tract cancer - Published
- 2021
- Full Text
- View/download PDF
248. Taxonomy of rare genetic metabolic bone disorders.
- Author
-
Masi, L., Agnusdei, D., Bilezikian, J., Chappard, D., Chapurlat, R., Cianferotti, L., Devolgelaer, J.-P., Maghraoui, A., Ferrari, S., Javaid, M., Kaufman, J.-M., Liberman, U., Lyritis, G., Miller, P., Napoli, N., Roldan, E., Papapoulos, S., Watts, N., and Brandi, M.
- Subjects
- *
OSTEOPOROSIS , *APPLICATION software , *BIOMARKERS , *BONE regeneration , *BONE resorption , *DATABASES , *HORMONES , *GENETIC mutation , *OSTEOPENIA , *RESEARCH funding , *TERMS & phrases , *WORLD Wide Web , *PHENOTYPES , *GENOMICS , *GENETICS , *SOCIETIES - Abstract
Summary: This article reports a taxonomic classification of rare skeletal diseases based on metabolic phenotypes. It was prepared by The Skeletal Rare Diseases Working Group of the International Osteoporosis Foundation (IOF) and includes 116 OMIM phenotypes with 86 affected genes. Introduction: Rare skeletal metabolic diseases comprise a group of diseases commonly associated with severe clinical consequences. In recent years, the description of the clinical phenotypes and radiographic features of several genetic bone disorders was paralleled by the discovery of key molecular pathways involved in the regulation of bone and mineral metabolism. Including this information in the description and classification of rare skeletal diseases may improve the recognition and management of affected patients. Methods: IOF recognized this need and formed a Skeletal Rare Diseases Working Group (SRD-WG) of basic and clinical scientists who developed a taxonomy of rare skeletal diseases based on their metabolic pathogenesis. Results: This taxonomy of rare genetic metabolic bone disorders (RGMBDs) comprises 116 OMIM phenotypes, with 86 affected genes related to bone and mineral homeostasis. The diseases were divided into four major groups, namely, disorders due to altered osteoclast, osteoblast, or osteocyte activity; disorders due to altered bone matrix proteins; disorders due to altered bone microenvironmental regulators; and disorders due to deranged calciotropic hormonal activity. Conclusions: This article provides the first comprehensive taxonomy of rare metabolic skeletal diseases based on deranged metabolic activity. This classification will help in the development of common and shared diagnostic and therapeutic pathways for these patients and also in the creation of international registries of rare skeletal diseases, the first step for the development of genetic tests based on next generation sequencing and for performing large intervention trials to assess efficacy of orphan drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
249. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.
- Author
-
Palermo, A., D'Onofrio, L., Eastell, R., Schwartz, A., Pozzilli, P., and Napoli, N.
- Subjects
- *
RISK factors of fractures , *TYPE 2 diabetes complications , *BONE remodeling , *BIOMARKERS , *DATABASES , *HYPOGLYCEMIC agents , *TYPE 1 diabetes , *INCRETINS , *MEDLINE , *ONLINE information services , *OSTEOPOROSIS , *SYSTEMATIC reviews , *DISEASE complications - Abstract
Fracture risk is higher in older adults with type 2 diabetes and may be influenced by treatments for diabetes. Oral anti-diabetic drugs have different effects on bone metabolism. The purpose of this review is to describe the effects of these drugs on bone metabolism and fracture risk. Osteoporosis is a progressive skeletal disorder that is characterized by compromised bone strength and increased risk of fracture. This condition has become an important global health problem, affecting approximately 200 million people worldwide. Another chronic and highly prevalent condition is diabetes mellitus, which affects more than 380 million people; both type 1 and type 2 diabetes are risk factors for fracture. Type 2 diabetes, in particular, is associated with impaired bone strength, although it is characterized by normal or elevated bone mineral density. Several therapeutic strategies are available to achieve the best outcomes in the management of diabetes mellitus but these have different effects on bone metabolism. The purpose of this narrative review is to describe the effects of oral hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-dependent glucose transporter 2 inhibitors) on bone metabolism and on the risk of developing fragility fractures in patients with type 2 diabetes. Both diabetes and osteoporosis represent a significant burden in terms of healthcare costs and quality of life. It is very important to choose therapies for diabetes that ensure good metabolic control whilst preserving skeletal health. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
250. First World Consensus Conference on Pancreas Transplantation: Part II - recommendations
- Author
-
Jonathan A. Fridell, Gabriel C. Oniscu, Marcelo Perosa, Quirino Lai, Helmut Arbogast, Jean-Paul Squifflet, Paola Maffi, Axel Andres, Jose Oberholzer, Claudio Ricci, Eelco J.P. de Koning, Daniel Casanova, Osama Gaber, Stephen T. Bartlett, Giuseppe Orlando, Ugo Boggi, Peter Schenker, Giuseppe Maria Ettorre, Piero Marchetti, R. Paul Robertson, Jenny E. Gunton, Steven A. White, Sara Iacopi, Raja Kandaswamy, Robert Öllinger, Pablo Uva, Francesco Menichetti, Rainer W.G. Gruessner, Dixon B. Kaufman, Lainie Friedman Ross, Cinthia B. Drachenberg, Paolo Rigotti, Robert R. Redfield, José Davide, Joseph R. Scalea, Mario Miccoli, Fanny Buron, Chiara Terrenzio, Duck Jong Han, Vittorio Perrone, Henry Pleass, Laureano Fernandez Cruz, Hussein A. Khambalia, Walter Baronti, Lucrezia Furian, Thierry Berney, Donzilia Sousa Silva, Robert Langer, Emmanuel Morelon, Peter G. Stock, Niccolò Napoli, Peter J. Friend, Robert J. Stratta, Fabio Vistoli, Matthew Cooper, Massimo Cardillo, Shruti Mittal, Frantisek Saudek, Adamasco Cupisti, Federica Cipriani, Emanuele Federico Kauffmann, Lionel Badet, Monica Ortenzi, Massimo Rossi, Lorella Marselli, Christopher J.E. Watson, Enrico Benedetti, George W. Burke, Jon S. Odorico, Carlo Socci, Rossana Caldara, Julien Branchereau, Angelika C. Gruessner, Antonio Secchi, Flavia Neri, Takashi Kenmochi, Boggi, Ugo, Vistoli, Fabio, Andres, Axel, Arbogast, Helmut, Badet, Lionel, Baronti, Walter, Bartlett, Stephen T, Benedetti, Enrico, Branchereau, Julien, W Rd Burke, George, Buron, Fanny, Caldara, Rossana, Cardillo, Massimo, Casanova, Daniel, Cipriani, Federica, Cooper, Matthew, Cupisti, Adamasco, Davide, Josè, Drachenberg, Cinthia, de Koning, Eelco Jp, Ettorre, Giuseppe Maria, Fernandez Cruz, Laureano, Fridell, Jonathan, Friend, Peter J, Furian, Lucrezia, Gaber, Osama, Gruessner, Angelika C, Gruessner, Rainer W, Gunton, Jenny, Han, Duck Jong, Iacopi, Sara, Kauffmann, Emanuele Federico, Kaufman, Dixon, Kenmochi, Takashi, Khambalia, Hussein A, Lai, Quirino, Langer, Robert M, Maffi, Paola, Marselli, Lorella, Menichetti, Francesco, Miccoli, Mario, Mittal, Shruti, Morelon, Emmanuel, Napoli, Niccolò, Neri, Flavia, Oberholzer, Jose, Odorico, Jon, Öllinger, Robert, Oniscu, Gabriel, Orlando, Giuseppe, Ortenzi, Monica, Perosa, Marcelo, Perrone, Vittorio Grazio, Pleass, Henry, Redfield, Robert R, Ricci, Claudio, Rigotti, Paolo, Robertson, Paul R, Ross, Lainie, Rossi, Massimo, Saudek, Frantisek, Scalea, Joseph, Schenker, Peter, Secchi, Antonio, Socci, Carlo, Sousa Silva, Donzilia, Squifflet, Jean Paul, Stock, Peter, Stratta, Robert, Terrenzio, Chiara, Uva, Pablo, Watson, Christopher, White, Steven A, Marchetti, Piero, Kandaswamy, Raja, Berney, Thierry, Boggi, Ugo [0000-0002-7505-5896], Vistoli, Fabio [0000-0003-2115-4191], Andres, Axel [0000-0003-3329-0801], Arbogast, Helmut P [0000-0001-5410-8699], Badet, Lionel [0000-0002-9596-0279], Baronti, Walter [0000-0002-4532-3028], Bartlett, Stephen T [0000-0002-3980-2559], Benedetti, Enrico [0000-0003-1120-6058], Branchereau, Julien [0000-0002-8460-9352], Burke, George W [0000-0002-6888-2842], Buron, Fanny [0000-0003-0404-6746], Caldara, Rossana [0000-0001-7115-5681], Cardillo, Massimo [0000-0002-2776-2297], Casanova, Daniel [0000-0003-3863-5039], Cipriani, Federica [0000-0002-8651-5982], Cooper, Matthew [0000-0002-3438-9638], Cupisti, Adamasco [0000-0002-8995-936X], Davide, Josè [0000-0003-3174-2456], Drachenberg, Cinthia [0000-0002-3104-5661], de Koning, Eelco JP [0000-0002-1232-7022], Ettorre, Giuseppe Maria [0000-0002-7501-5472], Fernandez Cruz, Laureano [0000-0001-5652-1209], Fridell, Jonathan A [0000-0002-8708-1506], Friend, Peter J [0000-0003-0841-9685], Furian, Lucrezia [0000-0002-2264-7986], Gaber, Osama A [0000-0002-9444-3202], Gruessner, Angelika C [0000-0001-5961-5913], Gruessner, Rainer WG [0000-0002-2094-9817], Gunton, Jenny E [0000-0002-8127-9773], Han, Duck-Jong [0000-0002-0990-6824], Kauffmann, Emanuele Federico [0000-0001-7634-4844], Kaufman, Dixon [0000-0003-3615-0994], Kenmochi, Takashi [0000-0002-9090-8770], Khambalia, Hussein A [0000-0002-7553-3026], Lai, Quirino [0000-0003-1487-3235], Langer, Robert M [0000-0001-8349-1260], Maffi, Paola [0000-0001-5011-6499], Marselli, Lorella [0000-0002-6698-2962], Menichetti, Francesco [0000-0003-0824-7166], Miccoli, Mario [0000-0002-8632-6145], Mittal, Shruti [0000-0003-2390-5366], Morelon, Emmanuel [0000-0001-9928-1671], Napoli, Niccolò [0000-0003-2538-9158], Neri, Flavia [0000-0002-2677-8967], Oberholzer, Jose [0000-0002-1069-2501], Odorico, Jon S [0000-0003-1096-464X], Öllinger, Robert [0000-0002-4499-1673], Oniscu, Gabriel [0000-0003-1714-920X], Orlando, Giuseppe [0000-0002-6460-7974], Ortenzi, Monica [0000-0002-6508-6488], Perosa, Marcelo [0000-0002-8576-9761], Pleass, Henry [0000-0002-9814-0452], Redfield, Robert R [0000-0001-5986-3466], Ricci, Claudio [0000-0002-6638-4479], Rigotti, Paolo [0000-0002-8895-935X], Ross, Lainie F [0000-0002-7395-3000], Rossi, Massimo [0000-0001-5105-4656], Saudek, Frantisek [0000-0002-0448-4351], Scalea, Joseph R [0000-0001-8278-2859], Schenker, Peter [0000-0002-3607-6993], Secchi, Antonio [0000-0002-4208-5116], Socci, Carlo [0000-0002-3276-5556], Sousa Silva, Donzilia [0000-0002-7165-3581], Squifflet, Jean Paul [0000-0002-0467-7559], Stock, Peter G [0000-0002-5806-0167], Stratta, Robert J [0000-0001-7634-094X], Terrenzio, Chiara [0000-0002-0629-2134], Uva, Pablo [0000-0001-7317-3875], Watson, Christopher JE [0000-0002-0590-4901], Marchetti, Piero [0000-0003-4907-0635], Kandaswamy, Raja [0000-0003-4302-0119], Berney, Thierry [0000-0002-4230-9378], Apollo - University of Cambridge Repository, Boggi U., Vistoli F., Andres A., Arbogast H.P., Badet L., Baronti W., Bartlett S.T., Benedetti E., Branchereau J., Burke G.W., Buron F., Caldara R., Cardillo M., Casanova D., Cipriani F., Cooper M., Cupisti A., Davide J., Drachenberg C., de Koning E.J.P., Ettorre G.M., Fernandez Cruz L., Fridell J.A., Friend P.J., Furian L., Gaber O.A., Gruessner A.C., Gruessner R.W.G., Gunton J.E., Han D.-J., Iacopi S., Kauffmann E.F., Kaufman D., Kenmochi T., Khambalia H.A., Lai Q., Langer R.M., Maffi P., Marselli L., Menichetti F., Miccoli M., Mittal S., Morelon E., Napoli N., Neri F., Oberholzer J., Odorico J.S., Ollinger R., Oniscu G., Orlando G., Ortenzi M., Perosa M., Perrone V.G., Pleass H., Redfield R.R., Ricci C., Rigotti P., Paul Robertson R., Ross L.F., Rossi M., Saudek F., Scalea J.R., Schenker P., Secchi A., Socci C., Sousa Silva D., Squifflet J.P., Stock P.G., Stratta R.J., Terrenzio C., Uva P., Watson C.J.E., White S.A., Marchetti P., Kandaswamy R., and Berney T.
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Pancreas transplantation ,clinical research/practice ,Pancreas/simultaneous pancreas-kidney transplantation ,Quality of life ,Renal Dialysi ,Renal Dialysis ,Diabetes mellitus ,medicine ,Risk of mortality ,Humans ,Immunology and Allergy ,survey ,Pharmacology (medical) ,Survey ,Intensive care medicine ,Dialysis ,Kidney transplantation ,pancreas/simultaneous pancreas‐kidney transplantation ,Transplantation ,ddc:617 ,diabetes ,pancreas/simultaneous pancreas-kidney transplantation ,business.industry ,Diabetes ,Graft Survival ,medicine.disease ,Kidney Transplantation ,Diabetes Mellitus, Type 1 ,surgical procedures, operative ,diabete ,Clinical research/practice ,Quality of Life ,Life expectancy ,Special Articles ,Original Article ,Pancreas Transplantation ,business ,Human - Abstract
Funder: Fondazione Pisa, Pisa, Italy; Id: http://dx.doi.org/10.13039/100007368, Funder: Tuscany Region, Italy; Id: http://dx.doi.org/10.13039/501100009888, Funder: Pisa University Hospital, Pisa, Italy, Funder: University of Pisa, Pisa, Italy; Id: http://dx.doi.org/10.13039/501100007514, The First World Consensus Conference on Pancreas Transplantation provided 49 jury deliberations regarding the impact of pancreas transplantation on the treatment of diabetic patients, and 110 experts' recommendations for the practice of pancreas transplantation. The main message from this consensus conference is that both simultaneous pancreas-kidney transplantation (SPK) and pancreas transplantation alone can improve long-term patient survival, and all types of pancreas transplantation dramatically improve the quality of life of recipients. Pancreas transplantation may also improve the course of chronic complications of diabetes, depending on their severity. Therefore, the advantages of pancreas transplantation appear to clearly surpass potential disadvantages. Pancreas after kidney transplantation increases the risk of mortality only in the early period after transplantation, but is associated with improved life expectancy thereafter. Additionally, preemptive SPK, when compared to SPK performed in patients undergoing dialysis, appears to be associated with improved outcomes. Time on dialysis has negative prognostic implications in SPK recipients. Increased long-term survival, improvement in the course of diabetic complications, and amelioration of quality of life justify preferential allocation of kidney grafts to SPK recipients. Audience discussions and live voting are available online at the following URL address: http://mediaeventi.unipi.it/category/1st-world-consensus-conference-of-pancreas-transplantation/246.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.